Semler Scientific Inc. (NASDAQ:SMLR) Given Consensus Recommendation of "Buy" by Analysts

Key Points

• Semler Scientific Inc. has received a consensus recommendation of "Buy" from four brokerages, with an average 12-month target price of $74.25.
• Recent performance highlights include earnings per share of $5.04, significantly surpassing the consensus estimate, along with a net margin of 86.20%.
• Institutional investors now own approximately 49.37% of Semler Scientific's stock following various investments and stake increases in the second quarter.

Shares of Semler Scientific Inc. (NASDAQ:SMLR - Get Free Report) have earned an average recommendation of "Buy" from the four brokerages that are presently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a buy recommendation. The average 12-month target price among brokerages that have issued a report on the stock in the last year is $74.25.

A number of research firms recently commented on SMLR. Maxim Group lowered their price target on Semler Scientific from $95.00 to $80.00 and set a "buy" rating for the company in a research report on Friday, September 19th. Weiss Ratings restated a "hold (c)" rating on shares of Semler Scientific in a research note on Saturday, September 27th. Cantor Fitzgerald reduced their price objective on Semler Scientific from $61.00 to $60.00 and set an "overweight" rating for the company in a research note on Wednesday, August 6th. Finally, Benchmark reduced their price objective on Semler Scientific from $101.00 to $86.00 and set a "buy" rating for the company in a research note on Tuesday, September 23rd.

Semler Scientific Price Performance

SMLR stock traded down $0.80 during midday trading on Friday, reaching $30.56. The company had a trading volume of 1,150,149 shares, compared to its average volume of 760,737. Semler Scientific has a 1-year low of $24.20 and a 1-year high of $81.56. The company has a debt-to-equity ratio of 0.25, a current ratio of 0.60 and a quick ratio of 0.58. The stock has a 50 day moving average price of $31.82 and a 200-day moving average price of $35.22. The company has a market capitalization of $452.59 million, a price-to-earnings ratio of 12.58 and a beta of 1.41.

Semler Scientific (NASDAQ:SMLR - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $5.04 earnings per share for the quarter, topping the consensus estimate of ($0.27) by $5.31. The company had revenue of $8.22 million for the quarter, compared to analysts' expectations of $8.10 million. Semler Scientific had a return on equity of 43.84% and a net margin of 86.20%.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in SMLR. Corient Private Wealth LLC purchased a new stake in shares of Semler Scientific in the 2nd quarter valued at about $387,000. Nomura Holdings Inc. raised its stake in shares of Semler Scientific by 5.8% in the second quarter. Nomura Holdings Inc. now owns 37,824 shares of the company's stock worth $1,465,000 after purchasing an additional 2,062 shares during the last quarter. Tower Research Capital LLC TRC increased its position in Semler Scientific by 354.8% during the second quarter. Tower Research Capital LLC TRC now owns 1,819 shares of the company's stock valued at $70,000 after acquiring an additional 1,419 shares during the last quarter. BNP Paribas Financial Markets raised its stake in shares of Semler Scientific by 2,390.7% in the second quarter. BNP Paribas Financial Markets now owns 9,340 shares of the company's stock worth $362,000 after buying an additional 8,965 shares during the period. Finally, Ameriprise Financial Inc. raised its stake in Semler Scientific by 13.4% during the 2nd quarter. Ameriprise Financial Inc. now owns 28,819 shares of the company's stock valued at $1,116,000 after purchasing an additional 3,411 shares during the period. Institutional investors own 49.37% of the company's stock.

About Semler Scientific

Semler Scientific, Inc provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.